In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.
The long-term prognosis for most patients with mantle cell lymphoma (MCL) is poor, with median overall survival rates of 3 to 5 years. Because treatment is not curative, almost all patients will experience a relapse or find that their disease is refractory to treatment.
With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer
Several oral drugs are in development for both non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). â€œThere is different activity in different lymphoma types with different oral drugs and antibodies in development,â€ said Andrew D. Zelenetz, MD, PhD.